Details of the Drug Combination

General Information of Drug Combination (ID: DCI5YG8)

Drug Combination Name

ACER-001 Glycerol phenylbutyrate

Indication

Disease Entry	Status	REF
Urea Cycle Disorders	Phase 1	[1]

Component Drugs

ACER-001 DM9HJFJ

Glycerol phenylbutyrate DMDGRQO

N.A.

Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of ACER-001

Disease Entry	ICD 11	Status	REF
Maple-syrup-urine disease	5C50.D0	Investigative	[2]

Indication(s) of Glycerol phenylbutyrate

Disease Entry	ICD 11	Status	REF
Hepatic encephalopathy	DB99.5	Approved	[3]

Glycerol phenylbutyrate Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Aquaporin adipose (AQP7)	DEVOTU4	AQP7_HUMAN	Metabolism	[4]
Propanediol dehydrogenase (dhaT)	DEDI8VX	A0A0C1Q6R1_LACBR	Metabolism	[5]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00551200) Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Aquaporins in the human testis and spermatozoa - identification, involvement in sperm volume regulation and clinical relevance. Int J Androl. 2010 Aug 1;33(4):629-41.
5	Expression and characterization of a novel 1,3-propanediol dehydrogenase from Lactobacillus brevis. Appl Biochem Biotechnol. 2016 Jul;179(6):959-72.